About

ProCan® Technologies Limited is a not-for-profit research and clinical services company leveraging the capabilities and intellectual property developed within the ProCan research program at Children’s Medical Research Institute (CMRI) in Sydney, New South Wales, Australia.

Our vision is to enhance and maximise the outcomes of oncology research and clinical trials globally.

ProCan is the abbreviated name of The Australian Cancer Research Foundation International Centre for the Proteome of Human Cancer, a world-first initiative developed by Professors Roger Reddel AO and Phil Robinson, which launched in September 2016. It was established with a $10 million grant from ACRF, and received additional funding from CINSW, MRFF, Cancer Council, NBCF, and other organisations.

DIA mass spectrometry technology is used to rapidly and simultaneously measure the precise levels of many thousands of proteins in very small cancer biopsies.